highly significantP < 0.001
The published results showed that, compared with placebo, everolimus showed a highly significant improvement in radiologically defined PFS using both investigator (6.9 vs. 2.8 months, hazard ratio [HR] = 0.43; 95% confidence interval [CI], 0.35-0.54; P < 0.001) and independent reviewers’ assessment (10.6 vs. 4.1 months, HR = 0.36; 95% CI, 0.27-0.47; P < 0.001).[ 2 ] Based on these data, the US FDA approved everolimus for the treatment of appropriately selected postmenopausal women with advanced breast cancer.